Johnson & Johnson price target lowered to $143 from $155 at RBC Capital. RBC Capital analyst Glenn Novarro lowered his price target on Johnson & Johnson to $143 ahead of its Q2 results, saying the trends in the U.S. prescription drug market suggest that any upside in the company’s Pharmaceutical segment is unlikely. Novarro expects the management to affirm its FY18 guidance for operational growth and earnings, but warns that the revenue guidance may see a downgrade due to the recent USD strength. The analyst also lowered his FY18 revenue projections to $81.1B from $81.3B and FY19 forecast to $80.6B from $83.0B.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.